When President Donald Trump convened nuclear industry executives at the White House in May, it marked the public rollout of a major shift in US nuclear ...
So, you’re an executive officer (XO) — now what? Several key responsibilities fall within your scope, whether at the ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Spectators wave Chinese flags as military vehicles carrying DF-41 nuclear ballistic missiles roll during a parade to commemorate the 70th anniversary of the founding of Communist China in Beijing on ...
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Albany International Corp. (NYSE: AIN) announced today that it is exploring strategic alternatives for its structures assembly business, including a potential sale ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback